Home › Sarcoidosis › NCT03621553
Vitamin D Homeostasis in Sarcoidosis
Who can join
Ages 21 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Stable medical condition defined as no hospitalization or emergency room visit in the previous 3 months * No evidence of active pulmonary or systemic infection * No other active inflammatory disease, * No active malignancy. * Normal serum ionized calcium level Exclusion Criteria: * Hospitalization or emergency room visit in the previous 3 months * Evidence of active pulmonary or systemic infection * Evidence of active other inflammatory disease * Evidence of active malignancy * Elevated serum ionized calcium level
About the study
This study evaluates the relationship between vitamin-D status and severity of sarcoidosis, and the effects of vitamin-D repletion in vitamin-D insufficient patients with sarcoidosis. Half the patients with sarcoidosis who are vitamin-D insufficient will receive standard vitamin-D supplementation via standard regimen while the other half will receive a placebo. Sarcoidosis patients who are vitamin-D sufficient will also act as controls.
What is being tested
- Ergocalciferol (drug)
- Placebo (drug)
- Calcium Citrate with Vitamin D2 (drug)
Sponsor: University of Texas Southwestern Medical Center · Participants: 90 · Started: Jul 1, 2010
Contact the study team
- Connie Hsia, MD · Phone: 2146483426
- Khashayar Sakhaee, MD · Phone: 2146480324
Official record on ClinicalTrials.gov — NCT03621553
Locations in the U.S.
| Texas | University of Texas Southwestern Medical Center, and Parkland Health and Hospital System, Dallas |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.